Comparison of tau-PET tracers: Progress towards a universal measure

tau-PET 示踪剂的比较：通用测量的进展

• 批准号: 10169910
• 负责人: Oscar L. Lopez
• 金额: $ 24.49万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-15 至 2021-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10169910
• 关键词: Address; Adult; Aging; Alzheimer' s Disease; Alzheimer' s disease pathology; Alzheimer' s disease related dementia; Amyloid; Area; Behavioral Symptoms; Binding; Biological; Biological Markers; Biology; Brain; Brain imaging; Characteristics; Classification; Clinical; Clinical Data; Clinical assessments; Cognition; Cognition Disorders; Communication; Communities; Data; Data Collection; Data Set; Databases; Dementia; Deposition; Development; Diagnostic Imaging; Early Diagnosis; Early treatment; Enrollment; Environment; Epidemiology; Etiology; Evolution; Faculty; Family; Foundations; Functional disorder; Genetic; Genetic study; Goals; Guanosine Triphosphate; Human; Human Resources; Image; Imaging Device; Imaging Techniques; Imaging ligands; Individual; Institution; International; Investments; Lead; Ligands; Magnetic Resonance Imaging; Masks; Measures; Methodology; Methods; Monitor; Natural History; Neurobehavioral Manifestations; Outcome; Participant; Pathogenesis; Pathologic; Pathologic Processes; Patients; Performance; Positioning Attribute; Positron-Emission Tomography; Procedures; Protein Isoforms; Psychotic Disorders; Public Health; Recording of previous events; Reporting; Research; Research Personnel; Sampling; Sampling Studies; Scoring Method; Solid; Standardization; Structure; Structure of choroid plexus; Symptoms; Techniques; Technology; Testing; Tracer; Training Programs; Translational Research; Treatment Efficacy; Universities; Validation; Work; amyloid imaging; career; clinical biomarkers; clinical effect; cohort; comorbidity; demented; design; effective therapy; eligible participant; gray matter; head-to-head comparison; health care delivery; imaging agent; improved; insight; interdisciplinary approach; multidisciplinary; neuroimaging; neuropathology; neuropsychiatry; non-demented; novel; novel therapeutics; pre-clinical; programs; psychogenetics; radiotracer; ranpirnase; structured data; tau Proteins; tau aggregation; white matter

Overall: Summary/Abstract: The University of Pittsburgh Alzheimer’s Disease Research Center (PITT- ADRC) has shown a clear scientific evolution over the past three decades. Since our inception, we have advanced the areas of AD neuropsychiatry, genetics, natural history of AD, validation of clinical criteria, and clinico-pathological correlations, and have pioneered the development of PET amyloid tracers, which have transformed AD research. We have used a multidisciplinary approach to better understand the transition from normal cognition to dementia, have explored the biology of more aggressive forms of AD characterized by psychosis, and have made and contributed to new insights in genetics. This solid scientific background and investment in junior investigators has allowed the PITT-ADRC to develop areas of excellence, which form the foundation of our Center going forward. These are reflected in the Center’s cores, and most notably in the large number of studies we support in these areas in Pittsburgh and at national and international level. The PITT-ADRC is committed to remain at the forefront of the scientific efforts to understand the pathological processes involved in the etiology of AD. Along with the high level of research conducted by the PITT-ADRC, we are also dedicated to developing strong training programs to promote the careers of young investigators, consolidate the career of midlevel investigators, and to create strong ties with the community through educational and support programs. The PITT-ADRC is highly committed to leverage the strengths of the network of Centers to provide large numbers of samples and standardized clinical data collection from our participants. The PITT-ADRC has designed novel methodology that improves the accessibility of its database to local and national researchers, and it has been a key player in multiple studies that advanced the understanding of AD pathology and its possible implications for the development of novel treatments and other symptoms. Therefore, we provide an excellent environment that enhances cutting-edge research by bringing together a multidisciplinary team of investigators to study AD and other dementias, and to improve health care delivery. The methodology proposed in this application will lead us to the creation of a unique and well-characterized cohort of patients and normal control subjects assessed with state of the art clinical and biomarker methods. This will allow us to test multiple scientific hypotheses and to examine the short- and long-term public health outcomes of the pathophysiology of cognitive disorders in the adult. We believe that the PITT -ADRC will be at the center of the new era of AD research that will require a wealth of clinical and biological data, highly sophisticated biomarker methodologies, close inter-relationship among centers and institutions, creation and optimization of human resources, and enhanced communication with patients and families.

总体：摘要/摘要： 匹兹堡大学阿尔茨海默氏病研究中心（Pitt- 在过去的三十年中，ADRC）表现出明显的科学进化。自成立以来，我们有 提高了AD神经精神病学，遗传学，AD的自然历史，临床标准验证的领域以及 临床病理学相关性，并开创了具有PET淀粉样蛋白示踪剂的发展 转变的广告研究。我们已经使用了多学科的方法来更好地了解 对痴呆症的正常认知探索了以更具侵略性的广告形式的生物学 精神病，并为遗传学的新见解做出了贡献。这种扎实的科学背景和 对初级调查人员的投资使Pitt-Adrc能够发展出卓越领域，这些领域构成了 我们中心的基础。这些反映在中心的核心中，最著名的是 我们在匹兹堡以及国家和国际一级的这些地区提供了大量的研究。 Pitt-Adrc致力于保持科学努力的最前沿，以了解 AD病因涉及的病理过程。以及由 皮特 - 阿德里奇（Pitt-Adrc），我们还致力于制定强大的培训计划，以促进年轻人的职业 调查人员，合并中层调查人员的职业，并与社区建立牢固的联系 通过教育和支持计划。 Pitt-Adrc高度致力于利用中心网络的优势来提供大型 从我们的参与者那里收集样本和标准化临床数据的数量。 Pitt-Adrc拥有 设计了新方法，可以提高其数据库对本地和国家研究人员的可访问性， 它一直是多项研究的关键人物 对新疗法和其他症状的发展的可能影响。因此，我们提供了 优秀的环境，通过将一个多学科团队组合在一起来增强尖端研究 研究人员研究AD和其他痴呆症，并改善医疗保健提供。 本应用程序中提出的方法将导致我们创建一个独特而良好的特征 使用最先进的临床和生物标志物方法评估的患者和正常对照组的队列。 这将使我们能够检验多个科学假设并检查短期和长期公共卫生 成年人认知障碍的病理生理结果。 我们认为，PITT -ADRC将处于广告研究的中心，这将需要一个 丰富的临床和生物学数据，高度复杂的生物标志物方法，紧密的关系 在中心和机构中，人力资源的创建和优化，并增强了交流 与患者和家庭。